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Abstract
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality in American
women. Normal ovarian physiology is intricately connected to small GTP binding proteins of
the Ras superfamily (Ras, Rho, Rab, Arf, and Ran) which govern processes such as signal
transduction, cell proliferation, cell motility, and vesicle transport. We hypothesized that
common germline variation in genes encoding small GTPases is associated with EOC risk.
We investigated 322 variants in 88 small GTPase genes in germline DNA of 18,736 EOC
patients and 26,138 controls of European ancestry using a custom genotype array and
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logistic regression fitting log-additive models. Functional annotation was used to identify bio-
features and expression quantitative trait loci that intersect with risk variants. One variant,
ARHGEF10L (Rho guanine nucleotide exchange factor 10 like) rs2256787, was associated
with increased endometrioid EOC risk (OR = 1.33, p = 4.46 x 10−6). Other variants of interest
included another in ARHGEF10L, rs10788679, which was associated with invasive serous
EOC risk (OR = 1.07, p = 0.00026) and two variants in AKAP6 (A-kinase anchoring protein 6)
which were associated with risk of invasive EOC (rs1955513, OR = 0.90, p = 0.00033;
rs927062, OR = 0.94, p = 0.00059). Functional annotation revealed that the two ARHGEF10L
variants were located in super-enhancer regions and that AKAP6 rs927062 was associated
with expression of GTPase gene ARHGAP5 (Rho GTPase activating protein 5). Inherited var-
iants in ARHGEF10L and AKAP6, with potential transcriptional regulatory function and asso-
ciation with EOC risk, warrant investigation in independent EOC study populations.
Introduction
In 2017, in the United States, more than 21,000 women were expected to be diagnosed with
epithelial ovarian cancer (EOC), and more than 14,000 women were predicted to die from the
disease.[1] EOC is heterogeneous and therefore classified into major histological subtypes of
invasive disease—serous, endometrioid, clear cell, and mucinous–and two histological sub-
types of borderline disease–serous and mucinous. These histological subtypes have differences
in genetic and epidemiologic risk factors, molecular events during oncogenesis, response to
chemotherapy, and prognosis.[2]
Approximately 20% of the familial component of EOC risk is attributable to high-to-inter-
mediate risk gene mutations.[3] In European populations, genome-wide association studies
(GWAS) have identified more than 30 EOC susceptibility alleles, as reviewed previously.[4]
Known common genetic variants explain 3.9% of the inherited component of EOC risk, and
additional susceptibility loci are likely to exist, particularly for the less common, non-serous
histological subtypes.
Normal ovarian physiology is intricately connected to tightly regulated small GTP binding
proteins of the Ras superfamily (Ras, Rho, Rab, Ral, Arf, and Ran) which regulate key cellular
processes such as signal transduction, cell proliferation, cell motility, and vesicle transport.[5]
These proteins function in a highly coordinated manner through signaling networks and feed-
back loops within and among the small GTPase subfamilies.[6] The Rab and Ral GTPases are
thought to function in membrane trafficking in exocyst assembly and vesicle-tethering pro-
cesses;[7, 8] Rho-related proteins function to integrate extracellular signals with specific targets
regulating cell morphology, cell aggregation, tissue polarity, cell motility and cytokinesis.[5]
Ras family genes cycle between their inactive GDP forms in the cytoplasm and the active GTP-
bound forms on the plasma membrane and are associated with signaling pathways contribut-
ing to normal and aberrant cell growth.[9]
As regulation of the RAS signal transduction pathway involves a highly complex, highly
polymorphic machinery of genes, we conducted a large-scale candidate pathway association
study, hypothesizing that variation in small GTPase genes is associated with EOC risk.
Materials and methods
Variant selection
RAS pathway genes were selected based on the Cancer Genome Anatomy Project and review
of the published literature (www.pubmed.gov). Within 115 candidate genes, 6103 single
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nucleotide polymorphism (SNPs) were interrogated in early GWAS analysis of 7931 EOC
patients and 9206 controls;[10] 339 SNPs in 88 of these genes showed nominal evidence of
association with risk of EOC or of serous EOC (p<0.05 using all participants or North Ameri-
can participants only)[10] and were targeted in the present analysis (S1 Table).
Study participants and genotyping
We studied 18,736 EOC patients (10,316 of serous histology) and 26,138 controls who partici-
pated in Ovarian Cancer Association Consortium studies; all participants were of European
ancestry.[11] This included participants from the GWAS which was used for variant selection
(described above)[10] and an additional 10,243 patients and 16,932 controls. Genotyping used
a custom Illumina Infinium array. [11] SNPs were excluded according to the following criteria:
no genotype call; monomorphism; call rate less than 95% and minor allele frequency> 0.05 or
call rate less than 99% with minor allele frequency< 0.05; evidence of deviation of genotype
frequencies from Hardy-Weinberg equilibrium (p< 10−7); greater than 2% discordance in
duplicate pairs. Overall, 322 small GTPase gene SNPs were genotyped and passed QC; num-
bers of participants with data for each SNP vary, as some DNA samples failed QC for particular
SNPs. This study was reviewed and approved by the Mayo Clinic Institutional Review Board
as protocol 1367–05.
Genetic association
We followed STREGA guidelines for genetic association studies.[12] Unconditional logistic
regression treating the number of minor alleles carried as an ordinal variable (log-additive model)
was used to evaluate the association between each SNP and EOC risk adjusted for age, study site,
and principal components to account for residual differences in European ancestry. Six series of
analyses were conducted considering the following groups: all invasive EOC combined, each of
the four main invasive histological subtypes (serous, endometrioid, clear cell and mucinous), and
all borderline tumors combined. No corrections were made for multiple testing.
Functional annotation
For SNPs of interest, dbSUPER [13] and Haploreg v4.1[14] were used to evaluate publicly
available data for variant overlap with human super-enhancers,[15] known expression quanti-
tative trait loci (eQTL), GWAS hits, and other regulatory marks. In addition, we assessed cor-
relations between germline genotype with tumor expression levels (eQTL analysis) using 312
Mayo Clinic patients (226 serous, 54 endometrioid, 22 clear cell, 5 mucinous, and 5 of other
histological subtypes). Expression data were obtained using fresh frozen tumor RNA and Agi-
lent whole human genome 4×44 expression arrays and were analyzed in the form of log ratios
of signals from individual tumors compared to signals from a reference mix of 106 tumor sam-
ples[16, 17] versus signals from a reference mix of 106 tumor samples[16, 17]. Expression lev-
els for minor allele carriers versus non-carriers were compared using the Wilcoxon rank sum
statistic.
Results and discussion
Demographic and clinical characteristics of the study sample (18,736 EOC patients and 26,138
controls) have been described previously.[11] In brief, compared to controls, patients were
older, attained menarche at older ages, and had higher body mass index. As expected, most
tumors (57.6%) were of serous histology with 14.2% endometrioid, 7.1% clear cell, 6.5%
mucinous, and 14.6% other/unknown.
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From among 322 SNPs in 88 RAS pathway small GTPase genes, we observed that 99 SNPs
in 43 genes were nominally associated with EOC risk (p<0.05) (S2 Table). These associations
were from six separate analyses that evaluated all patients with invasive disease, patients with
one of the four main invasive histological subtypes, serous [n = 8,372], endometrioid
[n = 2,068], clear cell [n = 1,025] and mucinous [n = 943], as well as patients with borderline
tumors.
In ARHGEF10L, which encodes the Rho guanine nucleotide exchange factor 10-like pro-
tein, SNP rs2256787 was associated with invasive endometrioid EOC risk (OR = 1.33, 95% CI:
1.18–1.50, p = 4.5x10-6) (Table 1). (Fig 1) shows the ORs and 95% CIs associated with the G
allele at this SNP overall and by contributing study.
Three other variants were associated at p-value<10−4 (Table 1, S1, S2 and S3 Figs).
rs10788679 in an intron of ARHGEF10Lwas associated with risk of invasive serous EOC (OR =
1.07, 95% CI: 1.03–1.11, p = 2.6x10-4;); ARHGEF10L SNPs rs2256787 and rs10788679 are inde-
pendent (r2 = 0.02, 1000 Genomes Project EUR). In addition, rs1955513 was most strongly asso-
ciated with all invasive EOC risk (OR = 0.90, 95% CI: 0.85–0.95, p = 3.3x10-4). This variant lies
in an intron of A-kinase (PRKA) anchor protein 6 (AKAP6). Another variant in AKAP6, intro-
nic SNP rs927062, was also associated with all invasive EOC risk (p = 5.9x10-4); AKAP6SNPs
rs1955513 and rs927062 are in modest linkage disequilibrium (r2 = 0.15, 1000 Genomes Project
EUR).
We investigated whether the four variants of interest, rs2256787, rs10788679, rs1955513,
rs927062, which are all intronic, alter expression of their proximal GTPases, or coincide with
regulatory marks that may affect expression (Table 1). In publicly available databases,[13, 14]
the ARHGEF10L SNPs rs2256787and rs10788679 coincide with a human ovary super-
enhancer, a region of the genome with unusually strong enrichment for the binding of
Table 1. Association of variants in small GTPase genes with epithelial ovarian cancer risk (p-value<10−4) and functional annotation.
Genetic Association Functional Annotation
Gene SNP Chr:Position Alleles MAF Histology OR
(95%
CI)
P-
value
Conserved
site
eQTL Tissues with
enhancer histone
mark
Tissues
with
DNAse
site
In super-
enhancer
ARHGEF10L rs2256787 1:17,765,403 A/C 0.07 Endometrioid 1.33
(1.18–
1.50)
4.5 x
10−6
No No ESC, ESDR, IPSC,
FAT, STRM, BRST,
BRN, SKIN, VAS,
LIV, GI, HRT,
MUS, LNG, OVRY,
PANC
None Yes
rs10788679 1:17,789,549 A/G 0.42 Serous 1.07
(1.03–
1.11)
2.6 x
10−4
No No None None Yes
AKAP6 rs1955513 14:32,245,693 C/A 0.07 All invasive 0.90
(0.85–
0.95)
3.3 x
10−4
Yes No FAT, SKIN, VAS,
BRN, MUS, GI,
BLD
SKIN,
MUS,
MUS,
THYM,
BLD
No
rs927062 14:32,164,800 G/A 0.21 All invasive 0.94
(0.90–
0.97)
5.9 x
10−4
No Yes,
ARHGAP5
None GI No
SNP, single nucleotide polymorphism; alleles show minor/major; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; eQTL, expression quantitative
locus with p<0.05 in EOC tumors; histone marks and DNAse I hypersensitive sites from HaploReg v 4.1 indicating tissue types as defined therein; super enhancer
information based on the human super-enhancer database available at http://bioinfo.au.tsinghua.edu.cn/dbsuper/index.php; none of these SNPs had previous GWAS
associations with any phenotype based on the EBI GWAS catalog or resided within promoter histone marks; all SNPs are intronic to the gene indicated.
https://doi.org/10.1371/journal.pone.0197561.t001
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transcriptional coactivators in this tissue. As ARHGEF10L rs2256787 associated with endome-
trioid EOC risk, we were particularly interested in eQTLs in the 54 endometrioid patients;
however, there was no evidence of association between rs2256787 genotype and ARHGEF10L
expression in endometrioid EOC tumors or other tumor subtypes. In 312 invasive EOC
tumors, the G allele of AKAP6 rs927062 correlated with reduced expression of Rho GTPase
activating protein 5 (ARHGAP5), a GTPase ~150kb upstream of AKAP6 (β = -0.22, 95% CI:
-0.41 to -0.03, p = 6.6x10-3). Other unstudied variants may also be associated with expression
of ARHGAP5 (or may be more strongly associated than rs927062), thus future genome-wide
or pathway-based analysis of GTPase SNP-expression relationships are of great interest. In
other histology-specific eQTL analyses, none of the four variants tested were associated with
EOC tumor mRNA expression.
Conclusion
We investigated 322 SNPs in 88 genes encoding small GTP binding proteins of the Ras super-
family (Ras, Rho, Rab, Ral, Arf, and Ran) in germline DNA of over 17,000 EOC patients and
26,000 controls. The 88 genes were derived from G protein (guanine nucleotide-binding pro-
teins) signaling, Ras-GTPases, regulation of Rho GTPase protein signal transduction and acti-
vation of Rac GTPase activity. [18] Ras-GTPases are activated at the plasma membrane by
guanine nucleotide exchange factors (GEF) such as: son of sevenless homologs 1 and 2 (Dro-
sophila) (SOS-1 and SOS-2); Ras protein-specific guanine nucleotide-releasing factor 1
(GRF1); Rap guanine nucleotide exchange factor 1 (GRF2); and RasGEF domain family, mem-
bers 1A, 1B and 1C (RasGRF). They are inactivated by GTPase activating proteins (GAP)
which include RAS p21 protein activator (GTPase activating protein) 1 (p120RasGAP). GEF
factors are recruited to the plasma membrane by scaffold and adaptor complexes such as SHC/
Grb2 that associate with activated tyrosine kinase receptors (TKR).[19] These factors exchange
GTP for GDP on the Ras protein. The resulting GTP-Ras protein activates various down-
stream effectors such as MAP-kinase Raf-1 which activates the MEK/ERK gene regulation cas-
cade, a primary cell growth and anti-apoptosis pathway.[6] Ras-GTPases family members
regulate the action of other GTPase pathways involving Rap, Ral, Rac and Rho Ras-GTPase.
Ras-GTPases also regulate phosphoinositide 3-kinase (PI3K) and phospholipase C (PLC)
activities.[5] Several of these genes are mutated in ovarian tumors.[20]
Overall, analysis at only one SNP yielded a p-value < 10−5: rs2256787 in ARHGEF10L
which was associated with 33% increased endometrioid EOC risk. Of note, the experiment-
wide error rate for this SNP, accounting for the initial overall set of 6103 candidate SNPs
equals 0.027 (Bonferroni-corrected p-value 4.5 x 10−6 x 6103); additionally accounting for six
case groups analyzed, this value increases to 0.16 (Bonferroni-corrected p-value 4.5 x 10−6 x
6103 x 6). However, as SNPs, as well as case groups, are not independent, simulation studies
are necessary to derive an empirical p-value. Another ARHGEF10L SNP, rs10788679, in
showed the smallest p-value in analysis of serous EOC and was the second-most strongly asso-
ciated SNP in all analyses. ARHGEF10L is a member of the RhoGEF family GEFs that activate
Rho GTPases.[21] The Rho branch of the Ras super family encompasses 20 genes in humans,
of which Rho, Rac and Cdc42 are the best characterized. Rho GTPases regulate the actin cyto-
skeleton and control changes in cell morphology and cell motility triggered by extracellular sti-
muli. Rho GTPases are regulated by GDP/GTP exchange factors and GAPs. Members of this
Fig 1. Association of rs2256787 in the ARHGEF10L gene with invasive endometrioid EOC risk by study site and combined. Squares represent the estimated per-
allele odds ratio (OR) and are proportional to sample size for each study; lines indicate its 95% confidence interval (CI); source indicates contributing study;[11] MAF,
control minor allele frequency; PVal, per-allele p-value adjusted for age, site, and principal components to account for residual differences in European ancestry.
https://doi.org/10.1371/journal.pone.0197561.g001
Small GTPases and ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0197561 July 6, 2018 8 / 13
subfamily are activated by specific GEFs and are involved in signal transduction. SNPs in this
gene are also associated with obesity[22] and cutaneous basal cell carcinoma.[23]
The SNP most associated with risk of invasive EOC was rs1955513 in the AKAP6 gene. This
gene is involved in overall G protein signaling. SNPs in this gene are also associated with neu-
rologic functioning [24] and anorexia.[25] Functionally, rs927062 in AKAP6 was associated
with expression of the Rho GTPase activating protein 5, ARHGAP5, also known as p190 Rho-
GAP, which negatively regulates RHO GTPases. The p190 RhoGAP gene contains a carboxy-
terminal domain that functions as a GAP for the Rho family GTPases. In addition to its Rho-
GAP domain, p190 contains an amino-terminal domain that contains sequence motifs found
in all known GTPases.
In conclusion, our study identified potentially functional genetic variants in small GTPase
genes that may have roles in EOC susceptibility. To interpret these associations, we suggest
consideration of effect sizes and directionality in the context of the sets of histotype-specific
analyses conducted; whether a more conservative or liberal statistical significance threshold is
applied, the small set of variants highlighted for detailed functional follow-up remain the
same. A limitation of this work is that nearby imputed variants were not examined and thus
other ungenotyped variants may be driving the reported associations. Nonetheless, four vari-
ants in two genes show promising associations that have not been reported previously but
point to known pathways that are mutated in ovarian tumors. The results of our investigation
suggest that further assessment of this important pathway is warranted in additional collec-
tions of densely genotyped EOC patients and controls.
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are proportional to sample size for each study; lines indicate its 95% confidence interval (CI);
Source indicates contributing study [11]; MAF, control minor allele frequency; PVal, per-allele
p-value adjusted for age, site, and residual European principal components.
(TIFF)
S2 Fig. Association of rs1955513 in the AKAP6 gene with invasive EOC risk by study site
and combined. Squares represent the estimated per-allele odds ratio (OR) and are propor-
tional to sample size for each study; lines indicate its 95% confidence interval (CI); Source indi-
cates contributing study [11]; MAF, control minor allele frequency; PVal, per-allele p-value
adjusted for age, site, and residual European principal components.
(TIFF)
S3 Fig. Association of rs927062 in the AKAP6 gene with invasive EOC risk by study site
and combined. Squares represent the estimated per-allele odds ratio (OR) and are propor-
tional to sample size for each study; lines indicate its 95% confidence interval (CI); Source indi-
cates contributing study [11]; MAF, control minor allele frequency; PVal, per-allele p-value
adjusted for age, site, and residual European principal components.
(TIFF)
S1 Table. Results from prior published EOC GWAS results on the targeted 339 SNPs in 88
RAS pathway genes. More details are available upon request.
(XLS)
S2 Table. Results from EOC genetic association analysis on 99 SNPs in RAS pathway genes
with nominal p-value <0.05 in analysis of all invasive patients, patients with invasive
Small GTPases and ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0197561 July 6, 2018 9 / 13
serous, endometrioid, clear cell, or mucinous subtypes, and patients with borderline
tumors versus controls. More details are available upon request.
(XLSX)
Acknowledgments
We thank all the individuals who took part in this study and all the researchers, clinicians and
technical and administrative staff who have made possible the many studies contributing to this
work. In particular, we thank: D. Bowtell, A. deFazio, D. Gertig, A. Green, P. Parsons, N. Hay-
ward, P. Webb and D. Whiteman (AUS); G. Peuteman, T. Van Brussel and D. Smeets (BEL);
the staff of the genotyping unit, S LaBoissiere and F Robidoux (Genome Quebec); U. Eilber
(GER); L. Gacucova (HMO); P. Schurmann, F. Kramer, W. Zheng, T. W. Park, Simon, K. Beer-
Grondke and D. Schmidt (HJO); S. Windebank, C. Hilker and J. Vollenweider (MAY); the state
cancer registries of AL, AZ, AR, CA, CO, CT, DE, FL, GA, HI, ID, IL, IN, IA, KY, LA, ME, MD,
MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WYL.
The authors assume full responsibility for analyses and interpretation of these data (NHS); L.
Paddock, M. King, L. Rodriguez-Rodriguez, A. Samoila, and Y. Bensman (NJO); M. Sherman,
A. Hutchinson,N. Szeszenia—- Dabrowska, B. Peplonska, W. Zatonski, A. Soni, P. Chao and
M. Stagner (POL); C. Luccarini,P. Harrington the SEARCH team and ECRIC (SEA); I. Jacobs,
M. Widschwendter, E. Wozniak, N. Balogun, A. Ryan and J. Ford (UKO); Carole Pye (UKR);
A. Amin Al Olama, K. Michilaidou, K. Kuchenbaker (COGS). The Australian Ovarian Cancer
Study acknowledges the cooperation of the participating institutions in Australia and acknowl-
edges the contribution of the study nurses, research assistants and all clinical and scientific col-
laborators to the study. The complete Australian Ovarian Cancer Study Management Group
can be found at www.aocstudy.org (Georgia.Trench@qimrberghofer.edu.au). We would like to
thank all of the women who participated in these research programs.
Author Contributions
Data curation: Stacey J. Winham, Katja K. H. Aben, Hoda Anton-Culver, Natalia Antonen-
kova, Elisa V. Bandera, Yukie T. Bean, Matthias W. Beckmann, Line Bjorge, Natalia Bogda-
nova, Louise A. Brinton, Angela Brooks-Wilson, Fiona Bruinsma, Clareann H. Bunker,
Ralf Butzow, Karen Carty, Jenny Chang-Claude, Linda S. Cook, Daniel W Cramer, Julie M.
Cunningham, Cezary Cybulski, Agnieszka Dansonka-Mieszkowska, Evelyn Despierre, Jen-
nifer A. Doherty, Thilo Do¨rk, Andreas du Bois, Matthias Du¨rst, Douglas F. Easton, Diana
M. Eccles, Robert P. Edwards, Arif B. Ekici, Peter A. Fasching, Brooke L. Fridley, Aleksan-
dra Gentry-Maharaj, Graham G. Giles, Rosalind Glasspool, Marc T. Goodman, Jacek Gron-
wald, Philipp Harter, Alexander Hein, Florian Heitz, Michelle A. T. Hildebrandt, Peter
Hillemanns, Claus K. Hogdall, Estrid Høgdall, Satoyo Hosono, Edwin S. Iversen, Anna
Jakubowska, Allan Jensen, Bu-Tian Ji, Audrey Y. Jung, Beth Y. Karlan, Melissa Kellar, Lam-
bertus A. Kiemeney, Boon Kiong Lim, Susanne K. Kjaer, Camilla Krakstad, Jolanta Kupry-
janczyk, Diether Lambrechts, Sandrina Lambrechts, Nhu D. Le, Shashi Lele, Jenny Lester,
Douglas A. Levine, Zheng Li, Dong Liang, Jolanta Lissowska, Karen Lu, Jan Lubinski, Lene
Lundvall, Leon F. A. G. Massuger, Keitaro Matsuo, Valerie McGuire, John R. McLaughlin,
Iain McNeish, Usha Menon, Roger L. Milne, Francesmary Modugno, Kirsten B. Moysich,
Roberta B. Ness, Heli Nevanlinna, Kunle Odunsi, Sara H. Olson, Irene Orlow, Sandra Orsu-
lic, James Paul, Tanja Pejovic, Liisa M. Pelttari, Jenny B. Permuth, Malcolm C. Pike, Eliza-
beth M. Poole, Barry Rosen, Mary Anne Rossing, Joseph H. Rothstein, Ingo B.
Runnebaum, Iwona K. Rzepecka, Eva Schernhammer, Ira Schwaab, Xiao-Ou Shu, Yurii B.
Small GTPases and ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0197561 July 6, 2018 10 / 13
Shvetsov, Nadeem Siddiqui, Weiva Sieh, Honglin Song, Melissa C. Southey, Beata Spiewan-
kiewicz, Lara Sucheston-Campbell, Ingvild L. Tangen, Soo-Hwang Teo, Kathryn L. Terry,
Pamela J. Thompson, Lotte Thomsen, Shelley S. Tworoger, Anne M. van Altena, Ignace
Vergote, Liv Cecilie Vestrheim Thomsen, Robert A. Vierkant, Christine S. Walsh, Shan
Wang-Gohrke, Nicolas Wentzensen, Alice S. Whittemore, Kristine G. Wicklund, Lynne R.
Wilkens, Yin-Ling Woo, Anna H. Wu, Xifeng Wu, Yong-Bing Xiang, Hannah Yang, Wei
Zheng, Argyrios Ziogas, Alice W Lee, Celeste L. Pearce, Andrew Berchuck, Joellen M.
Schildkraut.
Formal analysis: Joe Dennis.
Resources: Thomas A. Sellers, Simon A. Gayther, Linda E. Kelemen, Georgia Chenevix-
Trench, Harvey A. Risch, Paul D. P. Pharoah, Ellen L. Goode, Catherine M. Phelan.
Writing – original draft: Madalene Earp, Jonathan P. Tyrer.
Writing – review & editing: Stacey J. Winham, Hui-Yi Lin, Ganna Chornokur, Katja K. H.
Aben, Hoda Anton-Culver, Natalia Antonenkova, Elisa V. Bandera, Yukie T. Bean, Mat-
thias W. Beckmann, Line Bjorge, Natalia Bogdanova, Louise A. Brinton, Angela Brooks-
Wilson, Fiona Bruinsma, Clareann H. Bunker, Ralf Butzow, Ian G. Campbell, Karen Carty,
Jenny Chang-Claude, Linda S. Cook, Daniel W Cramer, Julie M. Cunningham, Cezary
Cybulski, Agnieszka Dansonka-Mieszkowska, Evelyn Despierre, Jennifer A. Doherty, Thilo
Do¨rk, Andreas du Bois, Matthias Du¨rst, Douglas F. Easton, Diana M. Eccles, Robert P.
Edwards, Arif B. Ekici, Peter A. Fasching, Brooke L. Fridley, Aleksandra Gentry-Maharaj,
Graham G. Giles, Rosalind Glasspool, Marc T. Goodman, Jacek Gronwald, Philipp Harter,
Alexander Hein, Florian Heitz, Michelle A. T. Hildebrandt, Peter Hillemanns, Claus K.
Hogdall, Estrid Høgdall, Satoyo Hosono, Edwin S. Iversen, Anna Jakubowska, Allan Jensen,
Bu-Tian Ji, Audrey Y. Jung, Beth Y. Karlan, Melissa Kellar, Lambertus A. Kiemeney, Boon
Kiong Lim, Susanne K. Kjaer, Camilla Krakstad, Jolanta Kupryjanczyk, Diether Lam-
brechts, Sandrina Lambrechts, Nhu D. Le, Shashi Lele, Jenny Lester, Douglas A. Levine,
Zheng Li, Dong Liang, Jolanta Lissowska, Karen Lu, Jan Lubinski, Lene Lundvall, Leon F.
A. G. Massuger, Keitaro Matsuo, Valerie McGuire, John R. McLaughlin, Iain McNeish,
Usha Menon, Roger L. Milne, Francesmary Modugno, Kirsten B. Moysich, Roberta B.
Ness, Heli Nevanlinna, Kunle Odunsi, Sara H. Olson, Irene Orlow, Sandra Orsulic, James
Paul, Tanja Pejovic, Liisa M. Pelttari, Jenny B. Permuth, Malcolm C. Pike, Elizabeth M.
Poole, Barry Rosen, Mary Anne Rossing, Joseph H. Rothstein, Ingo B. Runnebaum, Iwona
K. Rzepecka, Eva Schernhammer, Ira Schwaab, Xiao-Ou Shu, Yurii B. Shvetsov, Nadeem
Siddiqui, Weiva Sieh, Honglin Song, Melissa C. Southey, Beata Spiewankiewicz, Lara
Sucheston-Campbell, Ingvild L. Tangen, Soo-Hwang Teo, Kathryn L. Terry, Pamela J.
Thompson, Lotte Thomsen, Shelley S. Tworoger, Anne M. van Altena, Ignace Vergote, Liv
Cecilie Vestrheim Thomsen, Robert A. Vierkant, Christine S. Walsh, Shan Wang-Gohrke,
Nicolas Wentzensen, Alice S. Whittemore, Kristine G. Wicklund, Lynne R. Wilkens, Yin-
Ling Woo, Anna H. Wu, Xifeng Wu, Yong-Bing Xiang, Hannah Yang, Wei Zheng, Argyr-
ios Ziogas, Alice W Lee, Celeste L. Pearce, Andrew Berchuck, Joellen M. Schildkraut, Susan
J. Ramus, Alvaro N. A. Monteiro, Steven A. Narod, Thomas A. Sellers, Simon A. Gayther,
Linda E. Kelemen, Georgia Chenevix-Trench, Harvey A. Risch, Paul D. P. Pharoah, Ellen L.
Goode, Catherine M. Phelan.
References
1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7–30. https://doi.
org/10.3322/caac.21387 PMID: 28055103
Small GTPases and ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0197561 July 6, 2018 11 / 13
2. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol. 2008; 27
(2):161–74. https://doi.org/10.1097/PGP.0b013e31815ea812 PMID: 18317227
3. Pharoah PD, Ponder BA. The genetics of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2002;
16(4):449–68. PMID: 12413928
4. Kar SP, Berchuck A, Gayther SA, Goode EL, Moysich KB, Pearce CL, et al. Common genetic variation
and susceptibility to ovarian cancer: current insights and future directions. Cancer Epidemiol Biomark-
ers Prev. 2017 [Epub ahead of print].
5. Pajic M, Herrmann D, Vennin C, Conway JR, Chin VT, Johnsson AK, et al. The dynamics of Rho
GTPase signaling and implications for targeting cancer and the tumor microenvironment. Small
GTPases. 2015; 6(2):123–33. https://doi.org/10.4161/21541248.2014.973749 PMID: 26103062
6. Just WW, Peranen J. Small GTPases in peroxisome dynamics. Biochim Biophys Acta. 2016; 1863
(5):1006–13. https://doi.org/10.1016/j.bbamcr.2016.01.004 PMID: 26775587
7. Li G, Marlin MC. Rab family of GTPases. Methods Mol Biol. 2015; 1298:1–15. https://doi.org/10.1007/
978-1-4939-2569-8_1 PMID: 25800828
8. Shirakawa R, Horiuchi H. Ral GTPases: crucial mediators of exocytosis and tumourigenesis. J Bio-
chem. 2015; 157(5):285–99. https://doi.org/10.1093/jb/mvv029 PMID: 25796063
9. Nussinov R, Tsai CJ, Chakrabarti M, Jang H. A new view of Ras Isoforms in cancers. Cancer Res.
2016; 76(1):18–23. https://doi.org/10.1158/0008-5472.CAN-15-1536 PMID: 26659836
10. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, et al. A genome-wide associa-
tion study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet. 2009; 41(9):996–
1000. https://doi.org/10.1038/ng.424 PMID: 19648919
11. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, et al. GWAS meta-analysis
and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 2013; 45(4):362–
70, 70e1-2. https://doi.org/10.1038/ng.2564 PMID: 23535730
12. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, et al. STrengthening the REporting of
Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med. 2009; 6
(2):e22. https://doi.org/10.1371/journal.pmed.1000022 PMID: 19192942
13. Khan A, Zhang X. dbSUPER: a database of super-enhancers in mouse and human genome. Nucleic
Acids Res. 2016; 44(D1):D164–71. https://doi.org/10.1093/nar/gkv1002 PMID: 26438538
14. Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators
and target genes for human complex traits and disease. Nucleic Acids Res. 2016; 44(D1):D877–81.
https://doi.org/10.1093/nar/gkv1340 PMID: 26657631
15. Hnisz D, Schuijers J, Lin CY, Weintraub AS, Abraham BJ, Lee TI, et al. Convergence of developmental
and oncogenic signaling pathways at transcriptional super-enhancers. Mol Cell. 2015; 58(2):362–70.
https://doi.org/10.1016/j.molcel.2015.02.014 PMID: 25801169
16. Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, et al. Prognostic and therapeutic rele-
vance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014; 106(10):
dju249.
17. Wang C, Winterhoff BJ, Kalli KR, Block MS, Armasu SM, Larson MC, et al. Expression signature distin-
guishing two tumour transcriptome classes associated with progression-free survival among rare histo-
logical types of epithelial ovarian cancer. Br J Cancer. 2016; 114(12):1412–20. https://doi.org/10.1038/
bjc.2016.124 PMID: 27253175
18. Hoon JL, Tan MH, Koh CG. The regulation of cellular responses to mechanical cues by Rho GTPases.
Cells. 2016; 5(2).
19. Fritz G, Henninger C. Rho GTPases: novel players in the regulation of the DNA damage response? Bio-
molecules. 2015; 5(4):2417–34. https://doi.org/10.3390/biom5042417 PMID: 26437439
20. McConechy MK, Ding J, Senz J, Yang W, Melnyk N, Tone AA, et al. Ovarian and endometrial endome-
trioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 2014; 27(1):128–34.
https://doi.org/10.1038/modpathol.2013.107 PMID: 23765252
21. Winkler S, Mohl M, Wieland T, Lutz S. GrinchGEF—a novel Rho-specific guanine nucleotide exchange
factor. Biochem Biophys Res Commun. 2005; 335(4):1280–6. https://doi.org/10.1016/j.bbrc.2005.08.
025 PMID: 16112081
22. Comuzzie AG, Cole SA, Laston SL, Voruganti VS, Haack K, Gibbs RA, et al. Novel genetic loci identi-
fied for the pathophysiology of childhood obesity in the Hispanic population. PLoS One. 2012; 7(12):
e51954. https://doi.org/10.1371/journal.pone.0051954 PMID: 23251661
23. Stacey SN, Gudbjartsson DF, Sulem P, Bergthorsson JT, Kumar R, Thorleifsson G, et al. Common vari-
ants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or
pigmentation traits. Nat Genet. 2008; 40(11):1313–8. https://doi.org/10.1038/ng.234 PMID: 18849993
Small GTPases and ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0197561 July 6, 2018 12 / 13
24. Davies G, Armstrong N, Bis JC, Bressler J, Chouraki V, Giddaluru S, et al. Genetic contributions to vari-
ation in general cognitive function: a meta-analysis of genome-wide association studies in the CHARGE
consortium (N = 53949). Mol Psychiatry. 2015; 20(2):183–92. https://doi.org/10.1038/mp.2014.188
PMID: 25644384
25. Wang K, Zhang H, Bloss CS, Duvvuri V, Kaye W, Schork NJ, et al. A genome-wide association study
on common SNPs and rare CNVs in anorexia nervosa. Mol Psychiatry. 2011; 16(9):949–59. https://doi.
org/10.1038/mp.2010.107 PMID: 21079607
Small GTPases and ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0197561 July 6, 2018 13 / 13
